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A Hidden Cause for Electrolyte Derangement in the ED: Gitelman Syndrome
Alexis Dunn, James Espinosa, Alan Lucerna, Kevin Dwyer
Department of Emergency Medicine, Rowan University SOM/Jefferson - NJ
Introduction:

Discussion:

Electrolyte derangements are a common finding in the emergency
department, whether incidental or the cause for presenting symptoms.
Gitelman syndrome (GS) can be the cause for recurrent hypokalemia and
hypomagnesemia. While often diagnosed when the patient is young, a
clinician should keep this on the differential when seeing repeated visits
with electrolyte deficiencies and treating them. Here we discuss a case
of how Gitelman syndrome has presented in the ED and what to learn
from it.

GS, also known as familial hypokalemia-hypomagnesemia, is
an autosomal recessive disorder that causes salt wasting in
the distal convoluted tubule (DCT). Specifically, the mutations
in the apical membrane of the DCT are SLC12A3, coding for
thiazide-sensitive sodium chloride cotransporter, and TRPM6,
which codes for DCT magnesium transport (Parmar, et al).
Symptoms of these mutations do not typically occur before
age 6 and often is diagnosed in adolescence or adulthood.
The prevalence is 1:40,000, with prevalence of heterozygotes
being 1% in Caucasian populations. This is one of the most
inherited renal tubule disorders, however Bartter syndrome
is the most important other genetic tubule disorder to
consider in differential diagnosis (Knoers, et al).

Case Presentation:
A 32-year-old male presented to the ED with a complaint of pain and
cramping to his right hand. He had a known history of Gitelman
Syndrome and was concerned about his potassium levels, despite taking
prescribed potassium supplements. The patient was also prescribed
amiloride to take at home. Other past medical history was positive for a
stroke. He denied any surgeries. Social history was positive for tobacco,
alcohol, and marijuana use. Vitals signs were blood pressure 117/71 mm
Hg, heart rate of 51 beats per minute (bpm), respiratory rate of 19
breaths per minute, temperature 96.9 degrees Fahrenheit orally, and a
pulse oximetry of 100% on room air. His Body Mass Index was 30.65
kg/M2 .

Conclusions:

Physical examination revealed a non-toxic, well appearing male.
Pertinent positives include tenderness to the right-hand dorsal
metacarpals. Pertinent negatives include no heart murmurs, no
adventitious lung sounds, no decreased range of motion of the hand, no
joint pain in the right hand, no skin changes over the right hand, no
decreased sensation of the right hand, and no increased capillary refill
time. Otherwise, exam was unremarkable.
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An x-ray was performed of the right hand showing no acute fracture and
normal soft tissue. Labs ordered in the ED included CBC, CMP,
magnesium, phosphorus, creatinine kinase, and urinalysis. Pertinent
results included CK of 286 U/L, magnesium of 1.1 mmol/L, potassium of
2.2 mmol/L, creatinine of 1.04 mg/dL, phosphorus of 1.8 mg/dL, and an
unremarkable urinalysis. The patient was treated with supplemental
potassium, magnesium and intravenous fluids in the ED. The patient
went on to be admitted for further electrolyte correction.

Figure 1: Nephron with focus on the distal convoluted tubule
where the pathology of Gitelman Syndrome occurs.

While Gitelman syndrome may not affect immediate
care in the ED, it is important to be aware of it and its
implications on symptoms that patients may present
with. Whether the patient has a history of GS and is
presenting for hypotension, or the patient is coming in
for muscle aches, it is imperative to be aware of what
electrolyte abnormalities to expect with GS patients
and what disposition to anticipate.
Parmar MS, Muppidi V, Bashir K. Gitelman Syndrome. 2021 Aug 10. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 29083583.
Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis. 2008 Jul 30;3:22.
doi: 10.1186/1750-1172-3-22. PMID: 18667063; PMCID: PMC2518128.
Ungaro CM, Odstrcil-Bobillo MS, Russo PM. Síndrome de Gitelman [Gitelman syndrome].
Medicina (B Aires). 2020;80(1):87-90. Spanish. PMID: 32044746.
Cotovio P, Silva C, Oliveira N, Costa F. Gitelman syndrome. BMJ Case Rep. 2013 Apr
11;2013:bcr2013009095. doi: 10.1136/bcr-2013-009095. PMID: 23585506; PMCID:
PMC3645279.
Blanchard A, Bockenhauer D, Bolignano D, Calò LA, Cosyns E, Devuyst O, Ellison DH, Karet
Frankl FE, Knoers NV, Konrad M, Lin SH, Vargas-Poussou R. Gitelman syndrome: consensus
and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
Conference. Kidney Int. 2017 Jan;91(1):24-33. doi: 10.1016/j.kint.2016.09.046. PMID:
28003083.
Roser M, Eibl N, Eisenhaber B, Seringer J, Nagel M, Nagorka S, Luft FC, Frei U, Gollasch M.
Gitelman syndrome. Hypertension. 2009 Jun;53(6):893-7. doi:
10.1161/HYPERTENSIONAHA.108.127993. Epub 2009 Apr 6. PMID: 19349556.

Due to the mutation causing blockade of salt absorption,
patients typically present with hypokalemia and
hypomagnesemia. However, the frequently acknowledged
clinical symptom is malaise. GS is often diagnosed via
laboratory findings (Ungaro, et al). Other common clinical
findings include muscle cramps, weakness, polydipsia,
paresthesias, palpitations, orthostatic hypotension, and salt
craving (Blanchard, et al). Electrolyte derangements in the
blood include hypokalemia, hypomagnesemia, metabolic
alkalosis, hypocalcemia. Urinary excretion of chloride and
sodium are increased. Renal function and anatomy of the
kidney on ultrasound are typically normal (Cotovio, et al). Of
note, a patient with use of thiazide diuretics could present
with similar findings. Treatment consists of highly encouraged
sodium intake, oral potassium and magnesium supplements.
If the case of GS is still causing symptoms of hypokalemia
with the supplements, oral potassium-sparing diuretics or
renin angiotensin system blockers may be added to the
treatment plan. There is also research on potential use of
NSAIDs as treatment (Blanchard, et al). GS patients are often
managed by Nephrology for several reasons. The electrolyte
balance can be difficult to achieve. GS patients blood
pressure regulation can also be difficult to manage given the
mechanism of the mutation (Roser, et al).

